ÂÜÀòÂÒÂ×

Anna Turetsky is a seasoned professional with a strong background in venture investments and board participation in the biotechnology sector. Currently serving as Principal of Venture Investments at The Mark Foundation for Cancer Research since November 2019, Anna has taken on multiple board observer roles at companies such as Hyku Biosciences, Vicinitas Therapeutics, Immunitas Therapeutics, Interius BioTherapeutics, C2i Genomics, and Accent Therapeutics, alongside a board member position at Verseau Therapeutics. Anna's expertise is further underscored by a PhD in Biophysics from Harvard University and a BA in Biochemistry, with additional studies in Fine Arts and Math from the University of Pennsylvania.